



5. TERBUTALINE SULFATE

- a) Pharmacology
 - (1) Stimulates beta-2 receptors located in the smooth muscle of bronchioles
 - (2) Causes relaxation of bronchospasm

- b) Pharmacokinetics
 - Relieves bronchospasm in acute and chronic airway disease with minimal cardiovascular effect

- c) Indications
 - (1) Asthma
 - (2) Reversible airway obstruction associated with bronchitis or emphysema

- d) Contraindications
 - (1) Patients under 12 years of age

- e) Adverse Effects
 - (1) Tachycardia
 - (2) Palpitations
 - (3) Nervousness
 - (4) Tremors
 - (5) Dizziness
 - (6) Nausea
 - (7) Vomiting

- f) Precautions
 - (1) Exercise caution when administering to patients with hypertension or cardiac history
 - (2) Monitor EKG

- g) Dosage
 - (1) Patients 12 years of age and older:
Administer 0.25 mg IM. May repeat one time after 15 minutes if there is not adequate improvement. Maximum total dose 0.5 mg IM.
 - (2) Patients less than 12 years of age: Not indicated